Anteris reports one‑year clinical results for DurAVR heart valve in high‑risk aortic stenosis patients
Anteris Technologies presented one‑year data from a study of 100 patients with severe aortic stenosis and small annuli who received the DurAVR transcatheter heart valve. Hospitalization for heart‑failure occurred in 1% of patients and the valve showed a mean pressure gradient of 8.9 mmHg. At one year, 96% of patients were in NYHA class I/II and all‑cause mortality was 6%. The study also reported a mean effective orifice area of 2.2 cm², no moderate or severe paravalvular leak and no valve‑related deaths.
Why it matters
The company said the results demonstrate durable valve performance and favorable clinical outcomes, which could support broader adoption of DurAVR and influence investor sentiment. The stock rose to $5.09 in after‑hours trading following the release.
Key facts
- 1The study enrolled 100 patients with severe aortic stenosis and small annuli. rttnews.com
- 21% of patients were hospitalized for heart failure during the first year. rttnews.com
- 3Mean pressure gradient was 8.9 mmHg. rttnews.com
- 4Mean effective orifice area was 2.2 cm². rttnews.com
- 596% of patients were in NYHA class I/II at one year, up from 39% before treatment. rttnews.com
- 6All‑cause mortality at one year was 6% (including two cardiovascular deaths). rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.